Is Bionano Genomics, Inc. (BNGO) a Buy, Sell, or Hold?
NASDAQ : BNGO
Bionano Genomics, Inc.
$1.17 USD
-$0.02 (-1.68%)
- Volume
- 12.01K
- Average Volume
- 149.81K
- Market Capitalization
- $13.43M
- P/E Ratio
- -0.21
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $5.50
- Year Low
- $1.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.84
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Albert A. Luderer |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | BNGO |
| CUSIP | 09075F404 |
| CIK | 0001411690 |
| Web | https://bionano.com |
| Phone | 858 888 7600 |
| Currency | USD |
| Employees | 98 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.45 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.84 |
| Quick Ratio | 1.59 |
| Cash Ratio | 0.64 |
Sales & Book Value
| Annual Sales | $28.51M |
| Price / Sales | 0.48 |
| Cash Flow | -3.54 |
| Price / Cash Flow | -0.71 |
| Price / Book | 0.17 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $175.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | -76.60% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$4.85 |
| Trailing P/E Ratio | -0.21 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$26.4M |
| Net Margin | -109.95% |
| Pretax Margin | -109.70% |
| Return on Equity | -71.38% |
| Return on Assets | -48.76% |
Financials Score
| AltmanZ Score | -16.24 |
| Piotroski Score | 4.00 |
| Working Capital | 17.75M |
| Total Assets | 64.8M |
| Ebit | -31.24M |
| Market Cap | 13.66M |
| Total Liabilities | 27.34M |
Poll Results
About Bionano Genomics, Inc. (NASDAQ:BNGO) Stock
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its anal ... ytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Bionano Announces Hiring of Chief Scientific Officer
2026-06-24 08:30:00
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In this role, Dr. Hastie will lead the company's global scientific strategy, innovation roadmap, and research initiatives, advancing Bionano's mission to expand the research application of its genome analysis technologies and to develop a clinical applications strategy.
2026-06-18 08:00:00
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM. Key highlights from studies of OGM presented at ESHG 2026: 35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.
2026-06-11 08:00:00
SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the utility of optical genome mapping (OGM) for the detection and characterization of structural variants (SVs) in studies of reproductive health and prenatal genetic disorders. Reproductive disorders including infertility and recurrent pregnancy loss are highly prevalent and very often carry a genetic component.
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-08 13:01:04
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
2026-05-28 09:55:54
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
2026-05-28 08:00:00
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures"). The Company used cash on hand to retire the Debentures, which were originally issued in May 2024 in the aggregate face value of $20,000,000.
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
2026-05-26 08:00:00
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM's potential to transform how this aggressive blood cancer is studied and understood.
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
2026-05-13 19:00:43
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Bionano Genomics, Inc. (BNGO) stock price?
-
Bionano Genomics, Inc.(NASDAQ:BNGO) stock price is $1.17 in the last trading session. During the trading session, BNGO stock reached the peak price of $5.5 while $1.06 was the lowest point it dropped to. The percentage change in BNGO stock occurred in the recent session was --1.68% while the dollar amount for the price change in BNGO stock was -$0.02.
-
BNGO's industry and sector of operation?
-
The NASDAQ listed BNGO is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of BNGO?
-
Jonathan Dixon | General Counsel & Secretary
Mark Adamchak | VP of Accounting, Principal Accounting Officer & Controller
Albert A. Luderer | Chairman, Interim CEO, Interim President & Interim Principal Financial Officer
Alka Chaubey FACMG | Chief Medical Officer
Mark Oldakowski | Chief Operating Officer -
How many employees does BNGO have?
-
Number of BNGO employees currently stands at 98. BNGO operates from 9540 Towne Centre Drive, San Diego, CA 92121, US.
-
Link for BNGO official website?
-
Official Website of BNGO is: https://bionano.com
-
How do I contact BNGO?
-
BNGO could be contacted at phone #858 888 7600 and can also be accessed through its website. BNGO operates from 9540 Towne Centre Drive, San Diego, CA 92121, US.
-
How many shares of BNGO are traded daily?
-
The average number of BNGO shares traded daily for last 3 months was 149.81K.
-
What is the market cap of BNGO currently?
-
The market value of BNGO currently stands at $13.43M with its latest stock price at $1.17